BackHarvard Bioscience Overview

Harvard Bioscience Net Tangible Assets

Harvard Bioscience's net tangible assets is $10M.

Get informed when a big investor buys or sells

+ Follow
Net Tangible Assets
$10.05M

Peer average / median

Loading

Harvard Bioscience Net Tangible Assets History

Loading

Harvard Bioscience vs. peers: Net Tangible Assets Comparison

Loading

Harvard Bioscience Net Tangible Assets Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Balance Sheet Breakdown

Current CashShort Term InvestmentsReceivablesInventoryOther Current AssetsCurrent AssetsLong Term InvestmentsProperty Plant EquipmentGoodwillIntangible AssetsOther AssetsTotal AssetsNet Tangible AssetsAccounts PayableOther Current LiabilitiesTotal Current LiabilitiesLong Term DebtOther LiabilitiesMinority InterestTotal Liabilities

Harvard Bioscience (HBIO) FAQ

Harvard Bioscience (HBIO) currently reports a net tangible assets of $10M as of March 2026. In the prior-year period, the figure was $0. Use the charts on this page to explore Harvard Bioscience's net tangible assets history and peer comparisons.

Harvard Bioscience's net tangible assets changed from $0 to $10M (period ending March 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Harvard Bioscience reported $10M in net tangible assets as of March 2026. In the prior-year period, the figure was $0. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current net tangible assets of $10M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Harvard Bioscience, and consider following HBIO for alerts when major investors trade the stock.

Harvard Bioscience is classified in the Healthcare sector. On net tangible assets, it currently shows $10M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing HBIO with unrelated industries.